Johnson & Johnson
Latest statistics and disclosures from Johnson & Johnson's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KVUE, FUSN, CVRX, PTGX, SWAV, and represent 94.97% of Johnson & Johnson's stock portfolio.
- Added to shares of these 6 stocks: KVUE (+$3.9B), SWAV (+$54M), NBTX (+$30M), NMRA (+$13M), CVRX (+$11M), LAB.
- Started 3 new stock positions in SWAV, LAB, KVUE.
- Reduced shares in these 9 stocks: Point Biopharma Global (-$6.7M), HLTH, NNOX, ACET, Somalogic, ALDX, PHGE, APLM, Catalyst Biosciences.
- Sold out of its positions in Catalyst Biosciences, HLTH, Point Biopharma Global, Somalogic, APLM.
- Johnson & Johnson was a net buyer of stock by $4.0B.
- Johnson & Johnson has $4.4B in assets under management (AUM), dropping by 1525.60%.
- Central Index Key (CIK): 0000200406
Tip: Access up to 7 years of quarterly data
Positions held by Johnson & Johnson consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Johnson & Johnson
Johnson & Johnson holds 22 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kenvue (KVUE) | 88.7 | $3.9B | NEW | 182M | 21.46 |
|
| Fusion Pharmaceuticals (FUSN) | 1.8 | $78M | 3.7M | 21.32 |
|
|
| CVRX (CVRX) | 1.7 | $75M | +17% | 4.1M | 18.21 |
|
| Protagonist Therapeutics (PTGX) | 1.6 | $71M | 2.4M | 28.93 |
|
|
| Shockwave Med (SWAV) | 1.2 | $54M | NEW | 167k | 325.63 |
|
| Legend Biotech Corporation Ads (LEGN) | 1.0 | $46M | 815k | 56.09 |
|
|
| Meiragtx Holdings (MGTX) | 0.9 | $40M | 6.6M | 6.07 |
|
|
| Nanobiotix Sponsored Ads (NBTX) | 0.8 | $37M | +486% | 5.6M | 6.50 |
|
| Neumora Therapeutics (NMRA) | 0.6 | $25M | +102% | 1.8M | 13.75 |
|
| Fate Therapeutics (FATE) | 0.6 | $25M | 3.4M | 7.34 |
|
|
| Procept Biorobotics Corp (PRCT) | 0.4 | $18M | 358k | 49.42 |
|
|
| Xencor (XNCR) | 0.4 | $17M | 748k | 22.13 |
|
|
| Arrowhead Pharmaceuticals (ARWR) | 0.2 | $7.1M | 248k | 28.60 |
|
|
| Vor Biopharma (VOR) | 0.1 | $2.5M | 1.1M | 2.37 |
|
|
| Nano-X Imaging Ord Shs (NNOX) | 0.0 | $1.6M | -50% | 159k | 9.77 |
|
| Aldeyra Therapeutics (ALDX) | 0.0 | $980k | -24% | 300k | 3.27 |
|
| Chardan Healthcare Acqu- Ord (PHGE) | 0.0 | $865k | -9% | 1.9M | 0.45 |
|
| Adicet Bio (ACET) | 0.0 | $857k | -50% | 365k | 2.35 |
|
| D Fluidigm Corp Del (LAB) | 0.0 | $845k | NEW | 312k | 2.71 |
|
| Clearside Biomedical (CLSD) | 0.0 | $260k | 170k | 1.53 |
|
|
| Tracon Pharmaceuticals (TCON) | 0.0 | $36k | 84k | 0.43 |
|
|
| Senseonics Hldgs (SENS) | 0.0 | $29k | 55k | 0.53 |
|
Past Filings by Johnson & Johnson
SEC 13F filings are viewable for Johnson & Johnson going back to 2021
- Johnson & Johnson 2024 Q1 filed May 10, 2024
- Johnson & Johnson 2023 Q3 filed Nov. 9, 2023
- Johnson & Johnson 2023 Q2 filed Aug. 2, 2023
- Johnson & Johnson 2023 Q1 filed May 11, 2023
- Johnson & Johnson 2022 Q4 filed Feb. 9, 2023
- Johnson & Johnson 2022 Q3 filed Nov. 10, 2022
- Johnson & Johnson 2022 Q2 filed Aug. 10, 2022
- Johnson & Johnson 2022 Q1 filed May 9, 2022
- Johnson & Johnson 2021 Q4 filed Feb. 14, 2022
- Johnson & Johnson 2021 Q3 restated filed Nov. 16, 2021
- Johnson & Johnson 2021 Q3 filed Nov. 12, 2021